TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04577326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: A single dose of M28z1XXPD1DNR CAR T cells will be instilled into the pleural cavity via a pleural catheter or through an interventional radiology-guided needle. Cohorts of 3 patients will be treated at each dose level, up to a maximum of 3 x 10\^7 T cells/kg or until the MTD has been reached.
Study: NCT00916110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 1.5 mg solution, single subcutaneous injection
Study: NCT02439970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Study: NCT01534169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
Study: NCT04574687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Techniques
Description: )Conventional treatment protocol including active and active-assissted ROM exercises. (b)Proprioceptive neuro-muscular facilitation techniques. (c)Neuromuscular Developmental Techniques.
Study: NCT00916110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 4 mg solution, single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 10 mg solution, single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 25 mg solution, single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 25 mg solution, single intravenous injection
Study: NCT00484939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
Study: NCT05084573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Single bolus injection 10mL 1.33% LB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard bupivacaine
Description: Single bolus 10mL 0.25% SB + continuous 300mL 0.2% SB @5mL/hr
Study: NCT01751386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Study: NCT00916110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 50 mg solution, single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 100 mg solution, single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 200 mg solution, single subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: 200 mg solution, single intravenous injection
Study: NCT05488990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO-Calcipotriol formulation 1
Description: Novel lipid based formulation (AKVANO) type 1 containing Calcipotriol (50 μg/g)
Study: NCT01751386

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04087187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Subject will be given AZD5718 Dose A tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Subject will be given AZD5718 Dose A tablet once daily
Study: NCT04574687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation Therapy
Description: (a) active range of motion (AROM) exercises (10 min), (b) reaching movement or object manipulation (10 min), and (c) UE functional tasks (15 min). + Conventional treatment protocol as in group A
Study: NCT03741400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neofect RAPAEL Smart Glove
Description: The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
Study: NCT05488990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO-Calcipotriol formulation 2
Description: Novel lipid based formulation (AKVANO) type 2 containing Calcipotriol (50 μg/g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO vehicle formulation 1
Description: Novel lipid based formulation (AKVANO) vehicle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKVANO vehicle formulation 2
Description: Novel lipid based formulation (AKVANO) vehicle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex solution
Description: Daivonex solution containing Calcipotriol (50 μg/g)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex cream
Description: Daivonex cream containing Calcipotriol (50 μg/g)
Study: NCT00837291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: CF101 tablets 1 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets BID
Study: NCT00502684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol, etodolac
Description: propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
Study: NCT00612664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD137 (4-1BB) (BMS-663513)
Description: IV solution, IV, until PD or toxicity
Study: NCT02822703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Active 20Hz
Description: Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
Study: NCT00612664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD137 (4-1BB) (BMS-663513)
Description: IV solution, IV, until PD or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD137 (4-1BB) (BMS-663513)
Description: IV solution, IV, until PD or toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD137 (4-1BB) (BMS-663513)
Description: IV solution, IV, until PD or toxicity
Study: NCT01857479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled budesonide
Description: The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
Study: NCT02822703

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS Sham
Description: The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
Study: NCT03033667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: G group
Description: patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: group L
Description: patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group C
Description: Over night fasting with no supplementation
Study: NCT01727167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200ppm CO for one hour
Description: This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
Study: NCT01857479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Description: The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled amphotericin
Description: Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required \[max 10 puff/day\].~The first dose will be administered under direct supervision.
Study: NCT02800642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: The recommended dose for intravitreal aflibercept was 2 mg equivalent to 50 μL. Study treatment was administered at baseline and at monthly intervals until stabilization of disease. When stability was achieved, the treatment interval could be extended based on visual and anatomic outcomes as judged by the treating investigator.
Study: NCT04087187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Subject will be given AZD5718 Dose A tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Subject will be given AZD5718 Dose A tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Subject will be given AZD5718 Dose A tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Subject will be given AZD5718 Dose A tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Subjects will be given AZD5718 Dose B tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Subjects will be given AZD5718 Dose B tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Subjects will be given AZD5718 Dose B tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Subjects will be given AZD5718 Dose B tablet once daily
Study: NCT00458783

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged RBC storage
Description: Transfusion with oldest available matching RBCs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Short RBC storage
Description: Transfusion with youngest available matching RBCs
Study: NCT02372799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04087187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Subjects will be given AZD5718 Dose B tablet once daily
Study: NCT03266172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Modified Release
Description: GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Modified Release
Description: GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Modified Release
Description: GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Immediate Release
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Immediate Release
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
Study: NCT03779503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: midafilcon A
Description: midafilcon A 1 day daily disposable contact lens
Study: NCT02372799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Study: NCT04582994

Intervention type: BEHAVIORAL
Intervention: Beta tACS
Description: participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)

Intervention type: BEHAVIORAL
Intervention: Beta tACS
Description: participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Beta frequencies (22 Hz)

Intervention type: BEHAVIORAL
Intervention: Alfa tACS
Description: participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)

Intervention type: BEHAVIORAL
Intervention: Alfa tACS
Description: participants perform the Mental Time Travel task (duration 20 minutes), while tACS stimulation is delivered at Alfa frequencies (10 Hz)

Intervention type: BEHAVIORAL
Intervention: Sham
Description: participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered

Intervention type: BEHAVIORAL
Intervention: Sham
Description: participants perform the Mental Time Travel task (duration 20 minutes), while Sham tACS stimulation is delivered
Study: NCT01184027

Intervention type: BEHAVIORAL
Intervention: nutrition /swallowing counseling
Description: general nutrition and swalling information

Intervention type: BEHAVIORAL
Intervention: G-tube/swallowing intervention
Description: Patient will have active swallowing intervention with an SLP
Study: NCT04087187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Subjects will be given AZD5718 Dose C tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Subjects will be given AZD5718 Dose C tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Subjects will be given AZD5718 Dose C tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Subjects will be given AZD5718 Dose C tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Subjects will be given AZD5718 Dose C tablet once daily
Study: NCT03779503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: somofilcon A 1 day daily disposable contact lens
Study: NCT02907749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone and carvedilol
Description: Patients are treated with carvedilol in combination with spironolactone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Patients are treated with carvedilol only.
Study: NCT03344263

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: tests of attentional performance
Description: tests of attentional performance before and after 6 months of continuous positive airways pressure
Study: NCT04489121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
Study: NCT01203358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exosurf
Description: Infants received up to four intratracheal doses of the surfactant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Survanta
Description: Infants received up to four intratracheal doses of the surfactant.
Study: NCT00994591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic dosing
Description: Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
Study: NCT02203955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-Chain Fructooligosaccharide
Description: 4 chews (8.0 g scFOS) orally for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 4 chews (maltodextrin) daily for 12 months
Study: NCT02334488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium
Description: Experimental Arm
Study: NCT01189292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
Study: NCT02459275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP uP Protocol
Description: Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 10mg Intravenous (IV) every 6 hours (q6h) or 5mg IV q6h for renal failure will be started empirically concomitant with EN initiation. Gastric Residual Volume (GRV) will be checked every 4 hours and will be reinfused to the patient each time it is checked.
Study: NCT06264284

Intervention type: PROCEDURE
Intervention: epidural anesthesia
Description: Emergency cesarean section (red code) with epidural anesthesia

Intervention type: PROCEDURE
Intervention: general anesthesia
Description: Emergency cesarean section (red code) with general anesthesia
Study: NCT03825237

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)